Esperion Therapeutics: Another IPO After Pfizer Abandons The Only Drug In Its Pipeline
Brand : This morning I saw Esperion Therapeutics (NASDAQ
: ESPR ) scroll by on the CNBC ticker tape and did a double-take. This biotech
company was one of my better investments in the early 2000s and it was ultimately acquired by Pfizer
) for more than $1 billion in 2004. Since I ...
Read the rest of this article on IPO Analysis from Seeking Alpha